Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBIT (2017 - 2025)

Puma Biotechnology's EBIT history spans 9 years, with the latest figure at $17.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 27.99% year-over-year to $17.1 million; the TTM value through Dec 2025 reached $37.3 million, up 20.45%, while the annual FY2025 figure was $37.3 million, 20.45% up from the prior year.
  • EBIT reached $17.1 million in Q4 2025 per PBYI's latest filing, up from $9.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $22.1 million in Q3 2024 to a low of -$16.6 million in Q2 2021.
  • Average EBIT over 5 years is $5.9 million, with a median of $5.8 million recorded in 2023.
  • Peak YoY movement for EBIT: crashed 333.31% in 2021, then skyrocketed 2091.25% in 2022.
  • A 5-year view of EBIT shows it stood at -$503000.0 in 2021, then surged by 2091.25% to $10.0 million in 2022, then surged by 47.74% to $14.8 million in 2023, then dropped by 9.68% to $13.4 million in 2024, then increased by 27.99% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's EBIT are $17.1 million (Q4 2025), $9.6 million (Q3 2025), and $6.6 million (Q2 2025).